Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dissemination pattern of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.
Ishii Y, Tomita N, Suzuki T, Ishiyama Y, Kishimoto K, Yamamoto E, Koyama S, Hattori Y, Nakajima Y, Motohashi K, Takasaki H, Kawasaki R, Hashimoto C, Takemura S, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y. Ishii Y, et al. Among authors: kawasaki r. Leuk Lymphoma. 2015;56(9):2750-2. doi: 10.3109/10428194.2015.1010161. Epub 2015 Mar 6. Leuk Lymphoma. 2015. PMID: 25644745 No abstract available.
Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy.
Nakajima Y, Tomita N, Itabashi M, Miyashita K, Watanabe R, Miyazaki T, Tachibana T, Takasaki H, Kawasaki R, Tanaka M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Harano H, Motomura S, Ishigatsubo Y. Nakajima Y, et al. Among authors: kawasaki r. Leuk Res. 2015 Feb;39(2):198-203. doi: 10.1016/j.leukres.2014.11.030. Epub 2014 Dec 8. Leuk Res. 2015. PMID: 25541027 Clinical Trial.
R-CHOP therapy alone for limited-stage follicular lymphoma.
Tomita N, Suzuki T, Ishiyama Y, Miyashita K, Takahashi H, Numata A, Ito S, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Yamazaki E, Taguchi J, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y. Tomita N, et al. Among authors: kawasaki r. Leuk Res. 2015 Jun;39(6):582-5. doi: 10.1016/j.leukres.2015.03.008. Epub 2015 Apr 6. Leuk Res. 2015. PMID: 25866096 Clinical Trial.
The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.
Tomita N, Suzuki T, Miyashita K, Yamamoto W, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Taguchi J, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Kawamoto K, Sone H, Takizawa J. Tomita N, et al. Among authors: kawasaki r. Leuk Lymphoma. 2016 Dec;57(12):2763-2770. doi: 10.1080/10428194.2016.1195498. Epub 2016 Jun 20. Leuk Lymphoma. 2016. PMID: 27320054
Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma.
Koyama S, Fujisawa S, Watanabe R, Itabashi M, Ishibashi D, Ishii Y, Hattori Y, Nakajima Y, Motohashi K, Takasaki H, Kawasaki R, Hashimoto C, Yamazaki E, Koharazawa H, Takemura S, Tomita N, Sakai R, Motomura S, Nakajima H. Koyama S, et al. Among authors: kawasaki r. Int J Lab Hematol. 2017 Feb;39(1):112-117. doi: 10.1111/ijlh.12592. Epub 2016 Nov 24. Int J Lab Hematol. 2017. PMID: 27885817 Clinical Trial.
European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.
Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, Hashimoto C, Itabashi M, Ishibashi D, Nakajima Y, Tachibana T, Kawasaki R, Kuwabara H, Koharazawa H, Yamazaki E, Tomita N, Sakai R, Fujita H, Kanamori H, Ishigatsubo Y. Yamamoto E, et al. Among authors: kawasaki r. Cancer Sci. 2014 Jan;105(1):105-9. doi: 10.1111/cas.12321. Epub 2014 Jan 23. Cancer Sci. 2014. PMID: 24450386 Free PMC article.
Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.
Nakajima Y, Tomita N, Watanabe R, Ishiyama Y, Yamamoto E, Ishibashi D, Itabashi M, Koyama S, Takahashi H, Numata A, Takasaki H, Kawasaki R, Kuwabara H, Tanaka M, Hashimoto C, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y. Nakajima Y, et al. Among authors: kawasaki r. Med Oncol. 2014 Sep;31(9):185. doi: 10.1007/s12032-014-0185-3. Epub 2014 Aug 21. Med Oncol. 2014. PMID: 25142947
Evaluation of soluble interleukin-2 receptor and serum lactate dehydrogenase in malignant lymphoma.
Tomita N, Taguri M, Hashimoto C, Takasaki H, Fujimaki K, Motomura S, Koharazawa H, Takemura S, Fujita H, Yamazaki E, Kawasaki R, Taguchi J, Sakai R, Fujisawa S, Hattori Y, Kanamori H, Yamamoto W, Harano H, Ogawa K, Ishigatsubo Y. Tomita N, et al. Among authors: kawasaki r. Ann Hematol. 2015 Nov;94(11):1935-7. doi: 10.1007/s00277-015-2448-2. Epub 2015 Jul 25. Ann Hematol. 2015. PMID: 26208667 No abstract available.
[Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy].
Koharazawa H, Watanabe R, Hattori Y, Numata A, Kawasaki R, Kuwabara H, Hagihara M, Matsumoto K, Tanaka M, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Taguchi J, Tomita N, Fujita H, Sakai R, Harano H, Ishigatsubo Y, Fujisawa S. Koharazawa H, et al. Among authors: kawasaki r. Rinsho Ketsueki. 2015 Apr;56(4):392-9. doi: 10.11406/rinketsu.56.392. Rinsho Ketsueki. 2015. PMID: 25971269 Japanese.
485 results